O
FOLD

OrbiMed’s Amicus Therapeutics FOLD Stock Holding History

OrbiMed’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-729,900
Closed -$10.4M – 120
2025
Q4 		$10.4M Sell
729,900
-915,500
-56% -$8.99M 0.21% 80
2025
Q3 		$13M Sell
1,645,400
-640,000
-28% -$4.55M 0.3% 66
2025
Q2 		$13.1M Hold
2,285,400
– – 0.33% 54
2025
Q1 		$18.6M Hold
2,285,400
– – 0.44% 46
2024
Q4 		$21.5M Buy
2,285,400
+1,715,100
+301% +$17.8M 0.44% 51
2024
Q3 		$6.09M Hold
570,300
– – 0.11% 92
2024
Q2 		$5.66M Hold
570,300
– – 0.11% 86
2024
Q1 		$6.72M Sell
570,300
-235,700
-29% -$3.01M 0.12% 91
2023
Q4 		$11.4M Buy
+806,000
New +$9.15M 0.23% 75
2023
Q3 		– Sell
-1,856,400
Closed -$23.3M – 132
2023
Q2 		$23.3M Buy
1,856,400
+685,400
+59% +$8.13M 0.42% 67
2023
Q1 		$13M Buy
1,171,000
+655,000
+127% +$8.07M 0.25% 79
2022
Q4 		$6.3M Buy
+516,000
New +$5.81M 0.12% 87
2019
Q3 		– Sell
-518,309
Closed -$6.47M – 128
2019
Q2 		$6.47M Hold
518,309
– – 0.1% 100
2019
Q1 		$7.05M Buy
518,309
+195,300
+60% +$2.39M 0.11% 96
2018
Q4 		$3.09M Sell
323,009
-1,440,268
-82% -$15.8M 0.06% 112
2018
Q3 		$21.3M Sell
1,763,277
-5,309,223
-75% -$74.2M 0.26% 85
2018
Q2 		$110M Hold
7,072,500
– – 1.32% 25
2018
Q1 		$106M Buy
7,072,500
+1,500,000
+27% +$22.8M 1.32% 23
2017
Q4 		$80.2M Buy
+5,572,500
New +$76.6M 1.01% 32

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

OrbiMed's FOLD Position: Q1 2026 in Review

OrbiMed sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 729,900 shares — an estimated $10.4M sold.

OrbiMed first reported a position in FOLD in Q4 2017 and held it in 19 quarters. The position peaked at $110M in Q2 2018. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • OrbiMed reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • OrbiMed sold 729,900 Amicus Therapeutics shares in Q1 2026, an estimated $10.4M.
  • OrbiMed first reported a position in Amicus Therapeutics in Q4 2017 and held it in 19 quarters.
  • OrbiMed's Amicus Therapeutics position peaked at $110M in Q2 2018.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on OrbiMed's 13F filing for Q1 2026, filed 15 May 2026.